Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

Bevacizumab Versus Ranibizumab for Refractory Diabetic Macular Edema

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

Inclusion Criteria:

• Center-involving Diabetic macular edema unresponsive to LASER therapy performed at least 3 moths prior to inclusion;
• Best corrected visual acuity equal or worse than 20/40 and better than 20/800;
• Central subfield macular thickness greater than 300 µm

Exclusion Criteria:

• Aphakia
• High-risk proliferative diabetic retinopathy
• Previous treatment for DME in the past three months